FDA Liaison To CIR Would Maximize Agency Resources, Panel Says
This article was originally published in The Rose Sheet
Executive Summary
A formal FDA liaison to the Cosmetic Ingredient Review Expert Panel would provide the agency "an opportunity for a small FDA investment to be multiplied by the efforts of the CIR staff to access and describe published and unpublished safety test data, and...critically assess these data," CIR Chairman Wilma Bergfeld, MD, The Cleveland Clinic Foundation, maintains in Sept. 17 comments to FDA.